Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 18;12(2):218–226. doi: 10.1111/1759-7714.13748

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Kaplan‐Meier curves of the median OS among NSCLC patients with Ex20ins (a) , EGFR 20ins; , HER2 20ins, and progression‐free survival (PFS) of Ex20ins NSCLC patients to TKIs treatment (b) , EGFR 20ins; , HER2 20ins. There was no survival difference between EGFR exon 20 insertion and HER‐2 exon 20 insertion (23.3 vs. 35.0 months, P = 0.168). Also, PFS was similar between population with EGFR and HER2 Ex20ins who received TKI therapy (2.6 vs. 1.0 months, P = 0.989).

Inline graphic — Kaplan‐Meier curves of the median OS among NSCLC patients with Ex20ins (a) , EGFR 20ins; , HER2 20ins, and progression‐free survival (PFS) of Ex20ins NSCLC patients to TKIs treatment (b) , EGFR 20ins; , HER2 20ins. There was no survival difference between EGFR exon 20 insertion and HER‐2 exon 20 insertion (23.3 vs. 35.0 months, P = 0.168). Also, PFS was similar between population with EGFR and HER2 Ex20ins who received TKI therapy (2.6 vs. 1.0 months, P = 0.989).